Evidence map›Paper›PMID 38854931›Full record

ArticleNano today2024

Toward the scale-up production of polymeric nanotherapeutics for cancer clinical trials.

Md Musavvir Mahmud, Nikhil Pandey, Jeffrey A Winkles, Graeme F Woodworth, Anthony J Kim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nano today, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Md Musavvir MahmudFischell Department of Bioengineering, A. James Clarke School of Engineering, University of Maryland, College Park, MD, 20742, USA.
Nikhil PandeyDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Jeffrey A WinklesDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Graeme F WoodworthFischell Department of Bioengineering, A. James Clarke School of Engineering, University of Maryland, College Park, MD, 20742, USA.
Anthony J KimFischell Department of Bioengineering, A. James Clarke School of Engineering, University of Maryland, College Park, MD, 20742, USA.

Funding

Nanotherapeutic enhancement of interstitial thermal therapy for glioblastomaR01CA269995 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Huang Chiao Huang, Anthony J. Kim · 2023 to 2026
$2.5M
Impact of Fn14-targeted Nanoparticles for Triple-Negative Breast CancerR37CA218617 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI KIM, ANTHONY J. · 2018 to 2024
$2.4M
Nanotherapeutic treatment of the invasive glioblastoma microenvironmentR01NS107813 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI WOODWORTH, GRAEME F · 2019 to 2023
$2.0M
Novel drug delivery strategies for treatment of breast cancer brain metastasesI01BX005770 · VA · BALTIMORE VA MEDICAL CENTER · PI KIM, ANTHONY J. · 2022 to 2025
–
BLRD VA I01 BX005770NCI NIH HHS R01 CA269995NCI NIH HHS R37 CA218617NINDS NIH HHS R01 NS107813
6 · The paper itself

Abstract

Nanotherapeutics have gained significant attention for the treatment of numerous cancers, primarily because they can accumulate in and/or selectively target tumors leading to improved pharmacodynamics of encapsulated drugs. The flexibility to engineer the nanotherapeutic characteristics including size, morphology, drug release profiles, and surface properties make nanotherapeutics a unique platform for cancer drug formulation. Polymeric nanotherapeutics including micelles and dendrimers represent a large number of formulation strategies developed over the last decade. However, compared to liposomes and lipid-based nanotherapeutics, polymeric nanotherapeutics have had limited clinical translation from the laboratory. One of the key limitations of polymeric nanotherapeutics formulations for clinical translation has been the reproducibility in preparing consistent and homogeneous large-scale batches. In this review, we describe polymeric nanotherapeutics and discuss the most common laboratory and scale-up formulation methods, specifically those proposed for clinical cancer therapies. We also provide an overview of the major challenges and opportunities for scaling polymeric nanotherapeutics to clinical-grade formulations. Finally, we will review the regulatory requirements and challenges in advancing nanotherapeutics to the clinic.

Indexed as

cancerclinical translationcommercializationPolymeric nanotherapeuticsscale-up

Identifiers

PMID38854931
PMCPMC11155436

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.